IN2013MU02145A - - Google Patents

Download PDF

Info

Publication number
IN2013MU02145A
IN2013MU02145A IN2145MU2013A IN2013MU02145A IN 2013MU02145 A IN2013MU02145 A IN 2013MU02145A IN 2145MU2013 A IN2145MU2013 A IN 2145MU2013A IN 2013MU02145 A IN2013MU02145 A IN 2013MU02145A
Authority
IN
India
Prior art keywords
monoclonal antibody
purification
provides
desired monoclonal
purity
Prior art date
Application number
Other languages
English (en)
Inventor
Sanjay Bandyopadhyay
Sanjeev Kumar Mendiratta
Avanish Kumar Singh
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51655799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2013MU02145(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to TW103121726A priority Critical patent/TWI596107B/zh
Priority to ARP140102380A priority patent/AR096713A1/es
Priority to US14/895,432 priority patent/US9708365B2/en
Priority to AU2014300486A priority patent/AU2014300486B2/en
Priority to CA2911874A priority patent/CA2911874A1/en
Priority to SG11201509502XA priority patent/SG11201509502XA/en
Priority to EA201592192A priority patent/EA201592192A1/ru
Priority to IN2145MU2013 priority patent/IN2013MU02145A/en
Priority to EP14777867.4A priority patent/EP3013849B1/en
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to PCT/IN2014/000421 priority patent/WO2014207763A1/en
Priority to JP2015563045A priority patent/JP6039828B2/ja
Priority to MX2015016586A priority patent/MX350610B/es
Priority to BR112015031196A priority patent/BR112015031196A2/pt
Priority to NZ714079A priority patent/NZ714079A/en
Priority to CN201480031532.XA priority patent/CN105263947A/zh
Priority to KR1020157035759A priority patent/KR101683415B1/ko
Publication of IN2013MU02145A publication Critical patent/IN2013MU02145A/en
Priority to ZA2015/08258A priority patent/ZA201508258B/en
Priority to IL242649A priority patent/IL242649A/en
Priority to HK16105366.7A priority patent/HK1217344A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
IN2145MU2013 2013-06-25 2014-06-25 IN2013MU02145A (ja)

Priority Applications (19)

Application Number Priority Date Filing Date Title
TW103121726A TWI596107B (zh) 2013-06-25 2014-06-24 單株抗體之新穎純化方法
ARP140102380A AR096713A1 (es) 2013-06-25 2014-06-24 Proceso de purificación para anticuerpos monoclonales
KR1020157035759A KR101683415B1 (ko) 2013-06-25 2014-06-25 단일클론항체에 대한 정제 방법
JP2015563045A JP6039828B2 (ja) 2013-06-25 2014-06-25 モノクローナル抗体の精製方法
CA2911874A CA2911874A1 (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
SG11201509502XA SG11201509502XA (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
EA201592192A EA201592192A1 (ru) 2013-06-25 2014-06-25 Способ очистки моноклональных антител
IN2145MU2013 IN2013MU02145A (ja) 2013-06-25 2014-06-25
EP14777867.4A EP3013849B1 (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
US14/895,432 US9708365B2 (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
PCT/IN2014/000421 WO2014207763A1 (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
AU2014300486A AU2014300486B2 (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
MX2015016586A MX350610B (es) 2013-06-25 2014-06-25 Proceso para la purificacion de anticuerpos monoclonales.
BR112015031196A BR112015031196A2 (pt) 2013-06-25 2014-06-25 “processo de purificação de anticorpo monoclonal”
NZ714079A NZ714079A (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
CN201480031532.XA CN105263947A (zh) 2013-06-25 2014-06-25 单克隆抗体的纯化工艺
ZA2015/08258A ZA201508258B (en) 2013-06-25 2015-11-09 Purification process for monoclonal antibodies
IL242649A IL242649A (en) 2013-06-25 2015-11-18 Purification process of monoclonal antibody
HK16105366.7A HK1217344A1 (zh) 2013-06-25 2016-05-11 單克隆抗體的純化工序

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2145MU2013 IN2013MU02145A (ja) 2013-06-25 2014-06-25

Publications (1)

Publication Number Publication Date
IN2013MU02145A true IN2013MU02145A (ja) 2015-06-05

Family

ID=51655799

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2145MU2013 IN2013MU02145A (ja) 2013-06-25 2014-06-25

Country Status (19)

Country Link
US (1) US9708365B2 (ja)
EP (1) EP3013849B1 (ja)
JP (1) JP6039828B2 (ja)
KR (1) KR101683415B1 (ja)
CN (1) CN105263947A (ja)
AR (1) AR096713A1 (ja)
AU (1) AU2014300486B2 (ja)
BR (1) BR112015031196A2 (ja)
CA (1) CA2911874A1 (ja)
EA (1) EA201592192A1 (ja)
HK (1) HK1217344A1 (ja)
IL (1) IL242649A (ja)
IN (1) IN2013MU02145A (ja)
MX (1) MX350610B (ja)
NZ (1) NZ714079A (ja)
SG (1) SG11201509502XA (ja)
TW (1) TWI596107B (ja)
WO (1) WO2014207763A1 (ja)
ZA (1) ZA201508258B (ja)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI398554B (zh) * 2010-07-29 2013-06-11 Zhen Ding Technology Co Ltd 電鍍裝置
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
AR096713A1 (es) 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
CA2926588C (en) 2013-10-16 2020-07-21 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
EP3247718B1 (en) * 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
AU2016233557B2 (en) * 2015-03-13 2021-06-24 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities
JP6968055B2 (ja) * 2015-08-21 2021-11-17 ジェネンテック， インコーポレイテッド アフィニティークロマトグラフィーにおける宿主細胞タンパク質の低減方法
ES2897965T3 (es) 2015-08-21 2022-03-03 Hoffmann La Roche Procedimiento para la reducción de proteínas de célula huésped en cromatografía de afinidad
CA3013336A1 (en) 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
AU2017312785B2 (en) 2016-08-16 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
IL312194A (en) 2016-10-25 2024-06-01 Regeneron Pharma Methods and systems for analysis of chromatography data
US20200123251A1 (en) * 2016-10-28 2020-04-23 Merck Sharp & Dohme Corp. Purification Process for Removal of Tyrosine Sulfation Antibody Variants; Purified Compositions
MY197200A (en) 2016-12-23 2023-05-31 Serum Institute Of India Pvt Ltd Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
KR102087823B1 (ko) * 2017-05-16 2020-03-13 에이치케이이노엔 주식회사 친화성 크로마토그래피를 이용한 항체 또는 항체절편 정제 방법
EP3431168A1 (en) * 2017-07-19 2019-01-23 Bayer Aktiengesellschaft Élimination de médicament non lié après couplage conjugué anticorps-médicament
WO2019060062A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals Inc. METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM
CN108101987A (zh) * 2017-11-17 2018-06-01 安徽未名生物医药有限公司 一种重组抗TNF-α全人源单克隆抗体的纯化方法
CN110128538B (zh) * 2018-02-09 2022-08-26 鲁南制药集团股份有限公司 一种纯化抗cd20人鼠嵌合单克隆抗体的方法
CN111902720A (zh) 2018-03-21 2020-11-06 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
CA3103817A1 (en) 2018-07-02 2020-01-09 Regeneron Pharmaceuticals, Inc. Systems and methods for preparing a polypeptide from a mixture
EP3823594A1 (en) 2018-07-19 2021-05-26 Ichnos Sciences S.A. Liquid antibody formulation
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
CN111072773A (zh) * 2018-10-19 2020-04-28 菲鹏生物股份有限公司 抗体的纯化方法、抗体和应用
WO2020084503A1 (en) 2018-10-26 2020-04-30 Cadila Healthcare Limited A composition comprising antibody with reduced level of basic variants thereof
EP3643322A1 (en) * 2018-10-26 2020-04-29 Mabion SA Low aggregate anti cd20 ligand formulation
CN109320611B (zh) * 2018-10-31 2022-06-03 鼎康(武汉)生物医药有限公司 一种人鼠嵌合单克隆抗体生物类似药的纯化方法
CN111153993B (zh) * 2018-11-07 2024-06-28 正大天晴药业集团南京顺欣制药有限公司 抗TNF-α单克隆抗体的制备方法
CN109336969B (zh) * 2018-11-09 2021-02-12 杭州奕安济世生物药业有限公司 一种抗体的纯化方法
CN111269316B (zh) * 2018-12-04 2024-06-28 正大天晴药业集团南京顺欣制药有限公司 抗her2单克隆抗体的纯化方法
KR20220101168A (ko) 2019-11-22 2022-07-19 모르포시스 아게 이온 교환 크로마토그래피 동안 항체의 수율을 증가시키는 방법
WO2021139720A1 (zh) * 2020-01-08 2021-07-15 信达生物制药(苏州)有限公司 阿达木单抗纯化方法及其稳定组合物
KR102154952B1 (ko) * 2020-02-21 2020-09-10 프레스티지바이오로직스 주식회사 아달리무맙의 Non-Protein A 정제방법
WO2022245306A1 (en) * 2021-05-20 2022-11-24 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Protein purification by affinity chromatography
CN114133446A (zh) * 2021-12-31 2022-03-04 方坦思(上海)生物医药有限公司 单克隆抗体的纯化方法
CN115491328A (zh) * 2022-08-31 2022-12-20 深圳市卫光生物制品股份有限公司 一种大肠杆菌表达蛋白及其表达纯化方法
EP4335869A1 (en) 2022-09-07 2024-03-13 Bio T Biyoteknoloji Cozumleri Ve Uretim Anonim Resin and chromatography column that purifies antibodies with protease resistant small peptides

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
SI1308456T1 (sl) 1998-05-06 2008-02-29 Genentech Inc Ciscenje protiteles z ionsko izmenjevalno kromatografijo
ATE370961T1 (de) 1998-05-06 2007-09-15 Genentech Inc Reinigung von antikörpern durch ionenaustauschchromatographie
JP2002517406A (ja) * 1998-06-01 2002-06-18 ジェネンテック・インコーポレーテッド イオン交換クロマトグラフィーの使用による、凝集体からのタンパク質モノマーの分離
WO2004087761A1 (ja) 2003-03-31 2004-10-14 Kirin Beer Kabushiki Kaisha ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製
US20050163782A1 (en) 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
SE0400501D0 (sv) 2004-02-27 2004-02-27 Amersham Biosciences Ab Antibody purification
JP5199063B2 (ja) 2005-03-11 2013-05-15 ワイス・エルエルシー 弱分配クロマトグラフィー方法
KR101247836B1 (ko) 2005-06-17 2013-03-28 와이어쓰 엘엘씨 항 ａ 베타 항체의 정제 방법
US8263750B2 (en) 2006-03-16 2012-09-11 Amgen Inc. Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step
NZ571479A (en) 2006-04-05 2012-10-26 Abbott Biotech Ltd Antibody purification
KR20090064377A (ko) 2006-09-08 2009-06-18 와이어쓰 친화성 크로마토그래피를 사용하는 단백질 정제에 있어서 아르기닌 세척
CA2702637A1 (en) * 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using
US20100069617A1 (en) 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal by mixed mode chromatography on hydrophobic interaction media in the presence of protein-excluded zwitterions
WO2010030222A1 (en) 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal with multimodal anion exchangers in the presence of protein-excluded zwitterions
CA2932207A1 (en) 2008-10-20 2010-12-09 Abbvie Inc. Isolation and purification of antibodies using protein a affinity chromatography
ES2813398T3 (es) 2009-10-20 2021-03-23 Abbvie Inc Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A
EP2695889A1 (en) * 2009-12-29 2014-02-12 Dr. Reddy's Laboratories Limited Protein purification by ion exchange
WO2011089212A1 (de) 2010-01-22 2011-07-28 Boehringer Ingelheim International Gmbh Chromatographisches verfahren zur aufreinigung von fc enthaltenden proteinen
CN102179237A (zh) * 2010-04-26 2011-09-14 无锡加莱克色谱科技有限公司 一种用于分离、提纯单克隆抗体和抗体球蛋白的亲和色谱填料及其制备方法
JP6023715B2 (ja) * 2010-10-11 2016-11-09 アッヴィ・バハマズ・リミテッド タンパク質の精製方法
EP2649016B1 (en) 2010-12-06 2020-06-10 Pall Corporation Continuous processing methods for biological products
WO2012125735A1 (en) 2011-03-15 2012-09-20 Abott Laboratories An integrated approach to the isolation and purification of antibodies
US20140128577A1 (en) * 2011-06-24 2014-05-08 Dr. Reddy's Laboratories Limited Purification of chimeric protein
EP2773439A4 (en) * 2011-10-31 2015-07-01 Merck Sharp & Dohme CHROMATOGRAPHY METHOD FOR DECOMPOSING HETEROGENEOUS ANTIBODY AGGREGATES
WO2013075740A1 (en) 2011-11-23 2013-05-30 Sanofi Antibody purification method
PL3395423T3 (pl) * 2013-03-14 2024-03-18 Amgen Inc. Usuwanie wypłukanych ligandów do oczyszczania na zasadzie powinowactwa
CN105324393A (zh) * 2013-05-13 2016-02-10 米迪缪尼有限公司 具有最小单体分离的重组多克隆抗体多聚体的分离
AR096713A1 (es) 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales

Also Published As

Publication number Publication date
KR20160003311A (ko) 2016-01-08
AU2014300486B2 (en) 2016-06-30
AR096713A1 (es) 2016-01-27
JP2016525500A (ja) 2016-08-25
ZA201508258B (en) 2017-03-29
TWI596107B (zh) 2017-08-21
MX350610B (es) 2017-09-11
NZ714079A (en) 2017-05-26
BR112015031196A2 (pt) 2017-07-25
MX2015016586A (es) 2016-03-16
SG11201509502XA (en) 2015-12-30
EP3013849A1 (en) 2016-05-04
WO2014207763A1 (en) 2014-12-31
IL242649A (en) 2016-03-31
CA2911874A1 (en) 2014-12-31
US20160115195A1 (en) 2016-04-28
TW201512217A (zh) 2015-04-01
KR101683415B1 (ko) 2016-12-06
EA201592192A1 (ru) 2016-07-29
EP3013849B1 (en) 2017-09-13
JP6039828B2 (ja) 2016-12-07
US9708365B2 (en) 2017-07-18
HK1217344A1 (zh) 2017-01-06
CN105263947A (zh) 2016-01-20
AU2014300486A1 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
IN2013MU02145A (ja)
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX368177B (es) Proceso continuo de múltiples etapas para purificar anticuerpos.
MX2018006973A (es) Anticuerpos anti-cd73 humanizados.
JO3772B1 (ar) صيغة جسم مضاد لـ cgrp
MX364908B (es) Purificación de proteínas usando amortiguador bis-tris.
MX2023015125A (es) Composiciones y metodos para reducir la carga biologica en cromatografia.
PH12019502298A1 (en) Monoclonal antibody to pd-l1
WO2018162557A3 (en) Method for purifying proteins using silicate
EP3280444A4 (en) METHOD FOR CLEANING HETERODIMEROUS MULTISPECIFIC ANTIBODIES FROM PARENTAL HOMODIMERIC ANTIBODY TYPES
MX2016013416A (es) Nuevo proceso de purificacion de gonadotropina.
MX366112B (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
EA201400273A1 (ru) Способ снижения тромбоэмболического потенциала композиции, содержащей полученный из плазмы иммуноглобулин
MX2016000181A (es) Explicacion de la optimizacion de entrada de la cromatografia de intercambio ionico.
EP3575279A4 (en) PROCESS FOR PRODUCING HIGH CONCENTRATION ALCOHOL
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
EP3560956A3 (en) Methods of treating inflammatory diseases
MX2017013454A (es) Deteccion de moleculas de acido nucleico.
MY197993A (en) Method for protein purification
MX2015013182A (es) Purificacion analitica basada en la afinidad de compuestos bioterapeuticos para el control de bioprocesos.
MX2019011343A (es) Un procedimiento para la purificacion de fragmentos de anticuerpos recombinantes.
JOP20200106A1 (ar) جسم مضاد أحادي النسيلة مضاد لـ il-5r?
EP4239329A3 (en) Method and apparatus
WO2015004686A3 (en) A process for purification of efavirenz and intermediates thereof using chromatographic methods
MX2021007366A (es) Métodos de clarificación de cultivos celulares.